Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN5 | P54829 | 2/20 | 0.40 |
| ▸ | TYR | P14679 | 1/20 | 0.39 |
| ▸ | KIF11 | P52732 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.35 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.35 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17678036 | 0.78 | ALDH1A1 (0.50) | KIF11NPC1RAB9ATP53KDM4E | |
| SCHEMBL28730602 | 0.78 | CYP1A2 (0.42) | KIF11NOTUMNPC1RAB9ATP53 | |
| SCHEMBL18591736 | 0.78 | AKT1 (0.36) | CYP17A1 | |
| SCHEMBL24912727 | 0.77 | RXRA (0.46) | PTPN5TYRTP53KDM4EHPGD | |
| SCHEMBL197335 | 0.76 | KIF11 (0.52) | PTPN5TYRKIF11FFAR1NOTUM | |
| SCHEMBL18850046 | 0.76 | LRRK2 (0.40) | NPC1RAB9ATP53KDM4EHPGD | |
| SCHEMBL24301433 | 0.76 | ALDH1A1 (0.43) | NPC1RAB9ACYP17A1HPGDCYP1A2 | |
| SCHEMBL863158 | 0.75 | — | — | |
| SCHEMBL14679659 | 0.74 | ALDH1A1 (0.42) | NPC1RAB9ATP53KDM4EHPGD | |
| SCHEMBL15527629 | 0.74 | INMT (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873295-B2 | Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease | PETRA PHARMA CORPORATION (US) | 2024-01-16 | — | — | US | disclosed |
| US-20230365556-A1 | N-ACYL AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-11673887-B2 | N-acyl amino acid compounds and methods of use | PLIANT THERAPEUTICS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-20180093984-A1 | N-ACYL AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. | 2018-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11673887-B2 | N-acyl amino acid compounds and methods of use | ITGA1, ITGB1, ITGAL | PTPN5 2893/4885TYR 4458/4885KIF11 4178/4885 |
| US-11873295-B2 | Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease | PIK3CA, PIK3R4, PIK3R5 | PTPN5 774/4885TYR 1118/4885KIF11 3302/4885 |
| US-20230365556-A1 | N-ACYL AMINO ACID COMPOUNDS AND METHODS OF USE | ITGA1, ITGB1, ITGAL | PTPN5 2893/4885TYR 4458/4885KIF11 4178/4885 |
| US-20180093984-A1 | N-ACYL AMINO ACID COMPOUNDS AND METHODS OF USE | ITGA1, ITGB1, ITGAL | PTPN5 2893/4885TYR 4458/4885KIF11 4178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.